CTRI/2015/12/006426已完成未知
An open-label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study comparing pharmacokinetic and pharmacodynamic effects of PEG Neutrogen (pegfilgrastim) of Virchow Biotech, India with that of Neulastim (pegfilgrastim) of Roche following 6 mg subcutaneous injection in healthy, adult human subjects
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •.Provide written informed consent.
- •ii.Must be healthy, adult human beings within 20 and 45 years of age (both inclusive) weighing at least 50 kg.
- •iii.Having a body mass index between 18.5 and 29.9 (both inclusive), calculated as weight in Kg/height in m2.
- •iv.Must be of normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study. (Laboratory values must be within normal limits or considered by the physician / investigator to be of no clinical significance).
- •v.Female Subjects
- •of child bearing potential practising an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
- •surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
排除标准
- •Incapable of understanding the informed consent.
- •ii.Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.
- •iii.Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.
- •iv.Oral temperature is below 95.0°F or above 98.6°F.
- •v.Pulse rate below 50/min or above 100/min.
- •vi.History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs.
- •vii.Non-compliance to injections
- •viii.History of use of rhG-CSF during last week.
- •ix.Clinically significant abnormal laboratory values especially in terms of ANC, platelet or hemoglobin or liver or renal insufficiency at the time of screening.
- •x.Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.
- •xi.Consumption of grapefruit for the past ten days prior to the check-in.
- •xii.Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking during sample collection period.
- •xiii.Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period.
- •xiv.Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period.
- •xv.Confirmed positive in alcohol screening.
- •xvi.Confirmed positive in selected drug of abuse.
- •xvii.Participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study.
- •xviii.Confirmed positive in urine pregnancy test.
- •xix.Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study
研究者
相似试验
进行中（未招募）
Unknown
actoSpore® as an adjuvant in the treatment of Bacterial VaginosisCTRI/2023/05/052560Sami Sabinsa Group Limited
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-HRMenarini International Operations Luxembourg SA510
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthmatic patients.asthmaEUCTR2007-004608-11-FRovartis Pharma Services AG28
已完成
不适用
Boswellia serrata extract 200 mg capsules in subject with Irritable Bowel Syndrome.CTRI/2019/11/022190Inventia Healthcare Limited50
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 30 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on epithelial mucin stores and the safety and efficacy in COPD patients with symptoms associated with chronic bronchitis - Effects of BIBW 2948 on epithelial muciEUCTR2006-001975-40-IEBoehringer Ingelheim Limited60